Merck reports remigromig trial results in diabetic macular edema
Merck (NYSE:MRK) announced topline results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103) in adults with diabetic macular edema (DME).

Finance journalist at Grafa with years of experience covering Asia-Pacific financial markets at S&P Global, Mortgage Ezy, and GMA Network.
Merck (NYSE:MRK) announced topline results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103) in adults with diabetic macular edema (DME).
MediciNova (NASDAQ:MNOV) announced the completion of the last patient’s final visit in the double-blind portion of its Phase 2b/3 COMBAT-ALS trial evaluating MN-166 (ibudilast) for amyotrophic lateral sclerosis (ALS).
Uxin (NASDAQ:UXIN) reported revenue of RMB1,151.2 million for the quarter ended June 30, 2026, an increase of 74.9% from the same period last year.
AtlasClear Holdings (NYSE:ATCH) reported fiscal 2026 revenue of $20.1 million for the year ended June 30, 2026, representing an 85% increase from the prior year.
Galan Lithium (ASX:GLN) announced that its Hombre Muerto West Phase 1 lithium chloride operation in Argentina remains on track to deliver its first concentrate sales in Q4 2026.
The European Supervisory Authorities have warned quantum computing could undermine cryptography protecting financial systems and blockchains.
Native Mineral Resources (ASX:NMR) has produced 283.3 ounces of gold doré weighing 8.81 kilograms from its processing circuit.
The ABS reported that the nation's unemployment rate rose to 4.6% in August despite the economy adding 39,000 total jobs.
White House adviser Patrick Witt has defended President Donald Trump’s crypto ties after the Clarity Act failed in the Senate.
Elixinol Wellness (ASX:EXL) has entered into a binding agreement to acquire supplement platform Vitable for $2.5 million in shares.
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy